Our strengths: - PowerPoint PPT Presentation

1 / 42
About This Presentation
Title:

Our strengths:

Description:

QMT's super absorbent, microbicidal dressing performed superiorly or ... Hotels/Motels. Restaurants. Hospital Products. COMMERCIAL. Preservation ... – PowerPoint PPT presentation

Number of Views:70
Avg rating:3.0/5.0
Slides: 43
Provided by: natasha6
Category:
Tags: strengths

less

Transcript and Presenter's Notes

Title: Our strengths:


1
(No Transcript)
2
We rapidly deliver break-through products in
targeted fast growing civilian and military
health care markets where we can leverage our
leap-ahead core technologies.
  • Our strengths
  • Leading edge talent
  • Preeminent management team
  • Efficient corporate form
  • Advanced core technologies
  • Full product pipeline

The Bio-Tech Company for the New Millennium
3
Company
  • Founded in April 1997, Quick-Med Technologies is
    a bio-medical device company developing its
    proprietary, broad-based technologies for
    consumer healthcare markets and advanced military
    medical use.
  • QMTs two core technologies under development
    are
  • Ilomastat, and
  • NIMBUS

The Bio-Tech Company for the New Millennium
4
Scientific Team
  • Christopher D. Batich, Ph.D. Expert in
    Bio-Medical Engineering and Material Science
  • Gerald M. Olderman, Ph.D. Expert in Physical
    and Surface Chemistry
  • Gregory Schultz, Ph.D. Expert in Wound
    Healing and Skin Chemistry
  • William Toreki, Ph.D. Expert in Polymer
    Chemistry

The Bio-Tech Company for the New Millennium
5
University of Florida at Gainesville
  • Quick-Med Technologies has exclusive licenses
    from the University of Florida at Gainesville for
    the NIMBUS Ilomastat technologies.

The University of Florida is excited about its
new partnership with Quick-Med, it is an
excellent example of the proactive flexible
approach OTL has taken to assist promising new
companies developing UF technologies, which are
the basis for new products and enhancements to
existing product lines. We are hopeful that
through the efforts of our office and our new
partnership with Quick-Med, these technologies
will soon be applied to improving the human
condition. David Day, Director of the Office of
Technology Licensing (OTL) at the University of
Florida
The Bio-Tech Company for the New Millennium
6
Core Technology NIMBUS
  • Novel Intrinsically MicroBiocidal Utility
    Substrate (NIMBUS )
  • A family of advanced non-toxic polymers
    engineered to have antimicrobial, super
    absorbent, hemostatic and other properties with
    significant applications in the following
    markets
  • Institutional
  • Consumer
  • Industrial

The Bio-Tech Company for the New Millennium
7
Features of the NIMBUS Substrate
  • A non-extractable active agent is permanently
    attached to natural fibers.
  • The microbicide has a very broad spectrum of
    activity.
  • Bacterial resistance does not affect NIMBUS as
    it does with antibiotics because Nimbus works by
    the process of cell disruption.
  • Efficacy is not lost in the presence of proteins
    from food or body liquids.
  • High surface charge density enables the high
    performance.
  • NIMBUS exhibits a rapid action against
    bacteria, viruses and fungi.
  • Effective over a prolonged interval of at least
    seven days.
  • Flexible design allows the addition of dyes or
    other active agents.
  • A superabsorbent form is available as well.
  • The treatment is cost effective.
  • See following slide

The Bio-Tech Company for the New Millennium
8
Physical Disruption Of Bacterial Cells
  • From INDA "Presentation on Anti-microbial Agents
    Test Methods" at INTC 2002 Meeting, September
    26-26, 2002, Atlanta, Georgia, Curtis White,
    author.

The Bio-Tech Company for the New Millennium
9
Benefits of the NIMBUS Substrate
  • Highly effective against pathogenic bacteria.
  • Virucidal and fungicidal.
  • Quick and prolonged action.
  • Rapid absorbency.
  • High absorbent capacity.
  • Hemostatic action.
  • Eliminates bacteria that cause food and body
    odors.
  • Eliminates fungi that cause athletes foot and
    mildew.
  • Launderable.

The Bio-Tech Company for the New Millennium
10
Benefits of NIMBUS Large Economic Opportunity
  • Multiple applications
  • Flexible design
  • Patents pending
  • Exclusively available
  • Low cost

The Bio-Tech Company for the New Millennium
11
QMT NIMBUS Test Results
  • Broad spectrum microbicidal efficacy
  • Bacterial kill rates
  • Duration of action
  • Twice inoculated effectiveness
  • Zone of Inhibition
  • Hemostatic efficacy
  • Leachability
  • Cytotoxicity
  • Animal/Clinical safety tests

The Bio-Tech Company for the New Millennium
12
Broad spectrum Microbicidal efficacy
  • Kill levels for Percent killed
  • Staphylococcus aureus gt 99.9999
  • Eschericia coli gt 99.9999
  • Klebsiella pneumoniae gt 99.9999
  • Pseudomonas aeruginosa gt 99.9999
  • Proteus vulgaris gt 99.9999
  • Serratia marcescens gt 99.9999
  • Enterococcus faecalis gt 99.9999
  • Enterobacter aerogenes gt 99.9999
  • Candida albicans gt 99.9995
  • Bacteriophage MS-2 (an RNA virus) gt 99.994
  • Bacteriophage PRD1 (a DNA virus) gt 99.87
  • Tested in 10 bovine serum with eighteen hours
    of exposure

The Bio-Tech Company for the New Millennium
13
High kill rate starts in minutes lasts for hours
Percentage killed within indicated time
  • Tested in 10 bovine serum

14
Microbicidal Effect Is Prolonged
Duration of microbicidal efficacy in the presence
of 10 bovine serum
The Bio-Tech Company for the New Millennium
15
Repeated Inoculation Test Results
The results indicate that NIMBUS kills all but
one in a million bacteria per ml. NIMBUS is
more effective in eliminating over a million
cells per ml. than a similar bactericidal
treatment..
  • Repeated inoculation Colony forming units (cfu)
    on 0.1-gram gauze strips following inoculation
    with the indicated bacteria, overnight
    incubation, re- inoculation, and overnight
    incubation

The Bio-Tech Company for the New Millennium
16
Zone of Inhibition -- No Effect of Active Agent
Beyond Substrate
Effect of Gauze Extract on Bacterial
Growth Antimicrobial release test of gauze after
soaking in PBS for 4 hours
The Bio-Tech Company for the New Millennium
17
Zone of Inhibition controlGauze Sponges With No
Microbicide

  • Samples were inoculated with various volumes of
    5.8 x 10E3 cfu/mL of E. coli in PBS
    (counter-clockwise from top right 0.5 mL, 0.75
    mL, 2.0 mL, and 1.25 mL), and then incubated for
    15 hours at 37 degrees C tryptic soy agar (Difco)
    containing 0.01 TTC. Red color indicates areas
    of bacterial metabolism.

The Bio-Tech Company for the New Millennium
18
Zone of Inhibition Gauze Sponges With NIMBUS
  • Samples were inoculated with various volumes of
    5.8 x 10E3 cfu/mL of E. coli in PBS
    (counter-clockwise from top right 0.5 mL, 0.75
    mL, 2.0 mL, and 1.25 mL), and then incubated for
    15 hours at 37 degrees C tryptic soy agar (Difco)
    containing 0.01 TTC. Red color indicates areas
    of bacterial metabolism.

The Bio-Tech Company for the New Millennium
19
What Does Having No Zone Of Inhibition Mean?
  • What this test shows is that the microbicide is
    bonded and wont migrate from the substrate.
    That means its capacity to continue acting isnt
    depleted. It also means it does not have a
    microbicide that can escape from the material to
    which it has been bonded.
  • In the photo of the control the red area showing
    bacterial growth extends beyond the sponges on
    the lower half of the photo because the volumes
    (1.25ml. And 2.0 ml.) of inoculum exceed the
    capacity of the sponges which have no
    microbicide. All the area of the inoculum is
    therefore red.
  • In the photo of the NIMBUS sponges the samples
    in the lower two petri dishes show bacterial
    growth beyond the edges because the microbicide
    doesnt leach from the sponges and kill bacteria
    outside their periphery.

20
Rat Liver Hemorrhage Model
  • The liver of an anesthetized rat is placed on a
    Teflon slide. A stab injury is made to the liver
    with a scalpel, and a 1 cm disk of the test
    dressing is placed on the wound. Bleeding time is
    measured in 15 second intervals.

The Bio-Tech Company for the New Millennium
21
Rat Liver Hemorrhage Model
  • The cellulose sponge on the left is saturated
    while the QMT SAP sample on the right rapidly
    absorbs about 50x its weight in blood and stops
    the hemorrhage.

22
QMT SAP Dressing and Hemorrhage Control
The Bio-Tech Company for the New Millennium
23
Summary Hemorrhage Experiments
  • QMTs super absorbent, microbicidal dressing
    promotes clotting and rapidly controls major
    hemorrhage in rat liver laceration model.
  • QMTs super absorbent, microbicidal dressing
    performed superiorly or equivalently to other
    dressings that are approved for hemorrhage
    control in the rat liver laceration model
  • Avitene
  • Surgicel
  • Gel foam
  • Only QMT's dressing has microbicidal activity.
  • QMT's dressing can be constructed to be
    biodegradable.

The Bio-Tech Company for the New Millennium
24
Cytotoxicity Agent Not Toxic
  • Results of Cytotoxicity Test (ASTM F895-84)

    Agar Diffusion Method
  • USP 24 Section 87 Definitions
  • Grade 0 None - No detectable zone
  • Grade 1 Slight - Some malformed or degenerated
    cells
  • Grade 2 Mild - Zone limited to area under the
    specimen
  • Grade 3 Moderate - Zone extends 0.5 to 1.0 cm.
    beyond specimen
  • Grade 4 Severe - Zone extends 1.0 cm beyond
    specimen

25
Leachability Agent Is Not Extractable
  • Effect of Gauze Eluant on Bacterial Growth
  • Antimicrobial release after 42 hours on a rotary
    shaker

The Bio-Tech Company for the New Millennium
26
Animal/Clinical Test Results
  • Rabbit eye irritation
  • Results Non-irritating (1)
  • Primary Skin Irritation
  • Results Non-irritating (2)
  • Guinea Pig Dermal Sensitization
  • Results Non-sensitizing(3)
  • (1) Protocol CL 1003
  • (2) Protocol CL 1005
  • (3) Protocol CL 1015
  • Note All testing conducted by Geneva Test Labs,
    PO Box 140, Elkhorn, W I

The Bio-Tech Company for the New Millennium
27
MARKETS APPLICATIONS
  • COMMERCIAL
  • Preservation
  • Fungicide in interior wallboard or exterior
    siding

NIMBUS
  • CONSUMER
  • Wound Care
  • Apparel Footwear
  • Personal Products
  • Household Products
  • INSTITUTIONAL
  • Hotels/Motels
  • Restaurants
  • Hospital Products

28
Market Applications Consumer
The Bio-Tech Company for the New Millennium
29
Opportunities to Enhance Adult Diaper, Feminine
Care and Wipe products
The Bio-Tech Company for the New Millennium
30
Fabric/Personal Care NIMBUS Kills Problem
Bacteria
NIMBUS Efficacy (kill rate)
Bacteria or fungus
Problem to correct
99.99 99.99 99.94
Proteus vulgaris Pseudomonas aeruginosa Micrococcu
s luteus
Urine odor
Staphylococcus epidermidis Propionibacterium
acne Corynebacterium diphtheriae Micrococcus
luteus
Perspiration odor
99.99 99.99 99.99 99.94
Food Spoilage
99.99 99.99
Escherichia coli (beef, poultry) Salmonella
typhimurium (fish, poultry, beef, eggs)
Skin/diaper rashes athletes foot
Candida albicans Trichophyton mentagrophytes
99.99 99.48
The Bio-Tech Company for the New Millennium
31
Market Applications Institutional
  • Wound dressings
  • Hospital garments
  • Surgical drapes and apparel
  • Catheters
  • Urinary drainage systems
  • Blood collection containers
  • Facemasks

The Bio-Tech Company for the New Millennium
32
Advanced Wound Dressings Key Medical Features
Of Current Technology
  • Hemostatic (can add agents to promote healing)
  • Protease inhibitors
  • Vitamins
  • Collagen
  • Saline
  • Desired Permeability
  • Keep wounds moist
  • Permits oxygen passage
  • Microbicidal (bacteria, fungi, viruses)
  • Silver (Ag)
  • Iodine (I)
  • Chlorhexidine gluconate
  • Quaternaries
  • Super absorbent
  • Gels
  • Hydrocolloids
  • Hydrogels
  • Alginates

The Bio-Tech Company for the New Millennium
33
Drawbacks Of Current Absorbent Bactericidal
Technologies
  • Super Absorbent
  • Hydrocolloids can develop odors, and their
    clinical safety on infected wounds has not been
    established.
  • Alginates are unsatisfactory in dry, necrotic
    wounds.
  • Hydrogels cannot be left in place in contaminated
    wounds, and they may adhere to some wounds.
  • Hemostatic
  • No product offers this feature as well as the
    other two on this list.
  • Bactericidal
  • Quaternary and other biocide activity degrades in
    the presence of bodily fluids
  • Ag. treated dressings rely upon migration of the
    agent.
  • CHG must migrate into the wound and is rendered
    less effective in the presence of mucous or fatty
    acid exudates. It may also cause hypersensitivity
    reactions.
  • Povidone Iodine is less effective against
    Pseudomonas species.

The Bio-Tech Company for the New Millennium
34
Advanced Surgical Drapes Apparel Medical
Objectives
  • Restrict the transmission of bacteria.
  • Maintain a sterile field.
  • Protect patient and staff from bacterial
    contamination.
  • Prevent the soiling of patient and staff.
  • Provide modesty coverage.

The Bio-Tech Company for the New Millennium
35
Advanced Surgical Drape Apparel Drawbacks
Of Current Bactericidal Technologies
  • Not truly broad spectrum.
  • Not highly effective.
  • May be susceptible to blinding by body fluids.
  • May be leachable, thus possibly cytotoxic.

The Bio-Tech Company for the New Millennium
36
Advanced Surgical Drapes Apparel Key
Medical Features Of Current Technologies
  • Provide water repellent surfaces.
  • May be reinforced in areas vulnerable to
    challenge.
  • Drape reinforcement may be absorbent.
  • Bactericidal fenestrated area surface.
  • Soft, conformable fabrics.
  • Lightweight and comfortable.

The Bio-Tech Company for the New Millennium
37
NIMBUS Key Benefits Rapid FDA Approval
  • Class II medical device.
  • Predicate devices include ACTI-Gard Antimicrobial
    Incise Drape.
  • 510(K) approval process.

The Bio-Tech Company for the New Millennium
38
Microbicides in other hospital disposables
  • CSR Wrap products
  • Face Masks
  • Isolation Gowns, scrub clothing
  • Linens, towels, wipes
  • Dressings, bandages

The Bio-Tech Company for the New Millennium
39
Market Applications Industrial
  • Wood Preservation
  • Pesticides
  • Protective Clothing
  • Wipes
  • Food Handling
  • Filters
  • Paper
  • Packing Materials
  • Cork Bacteria (TCA)

The Bio-Tech Company for the New Millennium
40
Wood Preservation
  • Yellow pine samples 10 days after inoculation
    with white rot fungus.

The Bio-Tech Company for the New Millennium
41
Pesticide
  • Comparison of untreated yellow pine block
    (right), and NimbusTM treated yellow pine block
    (left), after 10 days exposure to subterranean
    termites.
  • Nimbus sample is unwashed.
  • Round spots in center are dimples on bottom of
    glass sample jar.
  • Samples are representative results of five
    replicates.

The Bio-Tech Company for the New Millennium
42
Contact Information
  • David Lerner - President
  • Tel 561.750.4202
  • Email dlerner_at_quickmedtech.com
  • Gerald M. Olderman - VP, Research Development
  • Tel 781.271.9893
  • Email jolderman_at_quickmedtech.com
  • URL www.quickmedtech.com

The Bio-Tech Company for the New Millennium
Write a Comment
User Comments (0)
About PowerShow.com